Attached files
| file | filename |
|---|---|
| EX-99.01 - EXHIBIT 99.01 - PALISADE BIO, INC. | v428765_ex99-01.htm |
| EX-99.02 - EXHIBIT 99.02 - PALISADE BIO, INC. | v428765_ex99-02.htm |
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 11, 2016
Neuralstem, Inc.
(Exact name of registrant as specified in Charter)
| Delaware | 001-33672 | 52-2007292 | ||
|
(State or other jurisdiction of incorporation or organization) |
(Commission File No.) | (IRS Employee Identification No.) |
20271 Goldenrod Lane, 2nd Floor, Germantown, Maryland 20876
(Address of Principal Executive Offices)
(301) 366-4960
(Issuer Telephone number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01 | Other Items. |
On January 11, 2016, Neuralstem, Inc. (the “Company”) announced the publication of “Human Cortical Neural Stem Cells Expressing Insulin-Like Growth Factor-1: A Novel Cellular Therapy for Alzheimer’s Disease,” in Stem Cells Translational Medicine. A copy of the press release is attached to this report as Exhibit 99.01.
Additionally, representatives of the Company will be making investor presentations the week of January 11, 2016, including a presentation at the Biotech Showcase 2016 being held at the Parc 55 San Francisco Hotel on Tuesday, January 12, 2016. A copy of the slides to be used in such presentations is attached to this report as Exhibit 99.02.
| Item 9.01 | Financial Statement and Exhibits. |
|
Exhibit No. |
Description |
|||
|
99.01 99.02 |
Press Release Dated January 11, 2016 Slides for Presentation |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: | January 11, 2016 | Neuralstem, Inc. |
| /s/ Richard Garr | ||
| By: Richard Garr | ||
| Chief Executive Officer |
|
|
INDEX OF EXHIBITS
|
|||
|
Exhibit No. |
Description |
|||
|
99.01 99.02
|
Press Release Dated January 11, 2016 Slides for Presentation |
|||